| Active substance | tebentafusp |
| Holder | Immunocore |
| Status | closed |
| Indication | HLA-A*02:01 positive patients with metastatic uveal melanoma |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 07/11/2023 |
Tebentafusp
Last updated on 07/11/2023